Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linong Ji

Showing results (431-440 of 588) with videos related to

Pageof 59
Sort By:
Diabetes, Obesity & Metabolism|August 22, 2025
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)Leili Gao, Linong Ji, Xin Yan, et al.
Diabetes, Obesity & Metabolism|September 13, 2019
Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical studyLinong Ji, Ningling Sun, Yunliang Zhang, et al.
Diabetes Care|January 20, 2022
ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in DiabetesJohn J Nolan, Anna R Kahkoska, Zhila Semnani-Azad, et al.
Diabetology & Metabolic Syndrome|February 7, 2025
Metabolic syndrome in type 1 diabetes: higher time above range and glycemic variability revealed by continuous glucose monitoring (CGM)Yayu Fang, Wei Liu, Xiaoling Cai, et al.
Current Medical Research and Opinion|September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 studyLinong Ji, Leili Gao, Zhifeng Cheng, et al.
Diabetes, Obesity & Metabolism|September 19, 2023
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapyLinong Ji, Jinmiao Lu, Leili Gao, et al.
The Lancet Regional Health. Western Pacific|October 21, 2024
Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 studyXiaoling Cai, Linong Ji, Mingxia Yuan, et al.
Diabetes, Obesity & Metabolism|July 2, 2021
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER studyFabrice Bonnet, Hungta Chen, Andrew Cooper, et al.
Diabetes Care|October 23, 2013
Nonlaboratory-based risk assessment algorithm for undiagnosed type 2 diabetes developed on a nation-wide diabetes surveyXianghai Zhou, Qing Qiao, Linong Ji, et al.
Journal of Diabetes|September 26, 2023
Adrenal limb thickness is associated with metabolism profiles in patients with diabetes: A cross-sectional studyYingning Liu, Xiantong Zou, Wei Zhao, et al.
Pageof 59

Showing results (431-440 of 588) with videos related to

Sort By:
Pageof 59
Diabetes, Obesity & Metabolism|August 22, 2025
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)Leili Gao, Linong Ji, Xin Yan, et al.
Diabetes, Obesity & Metabolism|September 13, 2019
Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical studyLinong Ji, Ningling Sun, Yunliang Zhang, et al.
Diabetes Care|January 20, 2022
ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in DiabetesJohn J Nolan, Anna R Kahkoska, Zhila Semnani-Azad, et al.
Diabetology & Metabolic Syndrome|February 7, 2025
Metabolic syndrome in type 1 diabetes: higher time above range and glycemic variability revealed by continuous glucose monitoring (CGM)Yayu Fang, Wei Liu, Xiaoling Cai, et al.
Current Medical Research and Opinion|September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 studyLinong Ji, Leili Gao, Zhifeng Cheng, et al.
Diabetes, Obesity & Metabolism|September 19, 2023
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapyLinong Ji, Jinmiao Lu, Leili Gao, et al.
The Lancet Regional Health. Western Pacific|October 21, 2024
Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 studyXiaoling Cai, Linong Ji, Mingxia Yuan, et al.
Diabetes, Obesity & Metabolism|July 2, 2021
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER studyFabrice Bonnet, Hungta Chen, Andrew Cooper, et al.
Diabetes Care|October 23, 2013
Nonlaboratory-based risk assessment algorithm for undiagnosed type 2 diabetes developed on a nation-wide diabetes surveyXianghai Zhou, Qing Qiao, Linong Ji, et al.
Journal of Diabetes|September 26, 2023
Adrenal limb thickness is associated with metabolism profiles in patients with diabetes: A cross-sectional studyYingning Liu, Xiantong Zou, Wei Zhao, et al.
Pageof 59